This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

AquaBounty Technologies Comment: Leading Scientists Say FDA Process For Approving Genetically Modified Food And Animals Unworkable

BOSTON, July 24, 2013 /PRNewswire/ -- Following is AquaBounty Technologies, Inc. comment on a paper published in today's Food Drug Law Institute's Food and Drug Policy Forum.  In this publication, three respected scientists with long U.S. Food and Drug Administration relationships finds the process used by the US FDA to regulate products from genetically modified animals so rigorous that it goes far beyond the legally required scientific analysis of food and environmental safety. 

"AquaBounty applied for US FDA approval twenty years ago.  We have complied with every regulatory requirement.  The company and the US FDA have been remarkably transparent," said Ronald L. Stotish, PhD, CEO of AquaBounty. "Yet our salmon, which grows to market weight in half the time and is the most studied fish in the world, still languishes in regulatory limbo.  This article describing the onerous and unworkable process helps explain why the FDA's hands have been tied by forces outside the agency's control."

The paper— the authors include a member for the independent advisory panel that reviewed the data for the world's first genetically modified food animal and two noted PhDs who testified at the FDA's public hearings on the topic— says the scrutiny required by this process forces the agency to respond to non-science-based claims and fall victim to political interference. The scientists say in the paper:

"Science is the basis for the FDA's considerations of all products... Lacking the background to interpret the science associated with GE [genetically engineered] animals as presented, activists often offer biased interpretations of the data and criticize the process by which the regulatory decision making goes forward.  Further, elected officials criticize agency actions on the basis of perceived risks to narrow constituencies.  Regulatory actions...should be based exclusively on science."

The paper confirms facts previously released many times by the US FDA, namely fish grown from AquAdvantage ® Salmon eggs:

"is as safe as food from conventional salmon" and that these salmon "will not have any significant impacts on the quality of the human environment of the United States ... when grown and produced under the conditions of use for the proposed action."

The authors also say unaccountable delays have jeopardized the FDA's ability to regulate rDNA animal products and have started to force these technologies offshore, despite their benefits.  They quote Dr. Calestous Juma, Harvard's Kennedy School of Government, that this nearly 20-year process:

"...sends a message to the rest of the world that science-based regulatory oversight as embodied in the FDA review process is subject to political intervention. Furthermore, it signals to the world that the United States may cede its leadership position in the agricultural use of biotechnology."

The paper also points out that when the science-based process is ignored, regulation can be influenced by those who don't understand basic biology and have financial interests.  For example, Rep. Don Young (R-AK) told the Washington Post his objective was to "put the company out of business" even though, the researchers drily note, it is biologically impossible for Atlantic salmon to mate with Pacific salmon -- even if they were able to overcome infertility, escape multiple redundant containment systems and swim hundreds, if not thousands, of miles to his state.

The authors make four policy recommendations to help protect the US FDA from non-science-based meddling as follows:

  • Maintain and strengthen a science-based regulatory review system for the evaluation of GE animals and continue formal consultation with all agencies with relevant expertise.
  • Require hypothesis-driven studies for regulatory evaluation detailing the biologically relevant issue(s) based upon the novel traits or phenotype(s) associated with the species/gene/insertion event combination.
  • Focus risk assessments on those unique risks associated with the GE animal application and evaluate them in relation to known risks associated with existing production systems.
  • Following submission of all pre-defined required data, impose finite response times for agency decisions at each point in the evaluation process to provide developers and investors with a predictable regulatory timeline for GE animals.

This paper, by noted research scientists, was written in response to a piece in the same issue of the FDLI journal written by a staff researcher at Food & Water Watch, a non-profit organization known to be opposed to biotechnology of any kind.  This piece by Food & Water Watch recycled claims previously disproven and dismissed by the academic community and the regulatory agencies themselves.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs